Crizotinib (PF-02341066)

Licensed by Pfizer Catalog No.S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 71 Publications

12 Customer Reviews

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Viability of Ba/F3 cells stably expressing DCTN1-ALK or EML4-ALK cDNAs after treatment with crizotinib (C). Ba/F3 cells transduced with lentiviral cDNA or empty vector were subjected to the assay, and the number of cells was counted at 72 hours.

    Oncologist, 2017, 22(2):158-164. Crizotinib (PF-02341066) purchased from Selleck.

    Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

  • (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
Targets
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 Mlu3R5l1d3SxeHnjJGF{e2G7 NXfIemZWPDhiaB?= M1GwXWROW09? MULDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochSUyNIF[xNVc1VCCvdYThcpQh[2:neIDy[ZN{cW6pIFXNUFQhf2m2aDDJR|UxKG:oIECuOlIh|ryP MYqyNVU4OjV6OR?=
BAF3 M2n1UmN6fG:2b4jpZ{BCe3OjeR?= NHrGZlM1QCCq M4\nV2ROW09? MoDsR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDMNVE6Pk1ibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCyMlIh|ryP NVzWWVJROjF3N{K1PFk>
BAF3 MUDDfZRwfG:6aXOgRZN{[Xl? NXLsPG8xPDhiaB?= NVvhfpl5TE2VTx?= NULZZ41{S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIFXNUFQuSUyNIIfpeIghUUN3MDDv[kAxNjJ6IN88US=> M2e4WVIyPTd{NUi5
Kelly MV7DfZRwfG:6aXOgRZN{[Xl? M{nhPWROW09? MmDPR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT4VtdHliY3XscJMh\XiycnXzd4lv\yCDTFugSlEyPzSOIH31eIFvfCC5aYToJGlEPTBib3[gNE41OiEQvF2= NIK2dHIzOTV5MkW4PS=>
SH-SY5Y M2fne2N6fG:2b4jpZ{BCe3OjeR?= NGC5R2RFVVOR M{XGeWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNJNVO\NWmgZ4VtdHNiZYjwdoV{e2mwZzDBUGshTjFzN{TMJI12fGGwdDD3bZRpKEmFNUCgc4YhOC53MzFOwG0> MmHINlE2PzJ3OEm=
SMS-KCN NYHjTZV1S3m2b4TvfIlkKEG|c3H5 M{T1c2ROW09? MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTUXMuU0OQIHPlcIx{KGW6cILld5NqdmdiQVzLJHIyOjd3UTDteZRidnRid3n0bEBKSzVyIH;mJFAvQTFizszN M1Pwe|IyPTd{NUi5
BAF3 MoWzR5l1d3SxeHnjJGF{e2G7 MnnDOFghcA>? NEfTb2tFVVOR MULDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochXGWuLVHMT{B4cXSqIFnDOVAhd2ZiMD6xPUDPxE1? Ml;KNlE2PzJ3OEm=
3T3 M{HqbWZ2dmO2aX;uJGF{e2G7 Mnq5NUBp MkTVSG1UVw>? MnHuTY5pcWKrdHnvckBw\iCUT16gZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEig{txO M3\sWVIyQDF{NEG0
3T3-E MlvKSpVv[3Srb36gRZN{[Xl? NHfHbXEyKGh? NEDNS4lFVVOR MXnJcohq[mm2aX;uJI9nKFSLRUKgZZN{\XO|ZXSg[5Jwf3SqIH\hZ5Rwei2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvPDR6IN88US=> NEfqWW4zOThzMkSxOC=>
A549 MYfLbY5ie2ViQYPzZZk> NY[1PVNYOSCq MVnEUXNQ NIi0PHVKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IHOtUWVVKGurbnHz[UBmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBJT0ZvaX7keYNm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjByODFOwG0> NXzsVmgyOjF6MUK0NVQ>
BAF3-BCL NVT5cJNRTnWwY4Tpc44hSXO|YYm= NEjCVmEyKGh? Mmr5SG1UVw>? NHXzPHlKdmirYnn0bY9vKG:oIFHCUEBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMT6xOVkh|ryP M4m4dFIyQDF{NEG0
HEK293 NFOzT4tHfW6ldHnvckBCe3OjeR?= M4rxZlEhcA>? MlfGSG1UVw>? MU\Jcohq[mm2aX;uJI9nKEG[TDDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5{OUSg{txO MV2yNVgyOjRzNB?=
HEK293 M{nCfmZ2dmO2aX;uJGF{e2G7 M3\OW|EhcA>? NVm0Opk3TE2VTx?= MkLxTY5pcWKrdHnvckBw\iCLUjDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOi56OEeg{txO M3XkVlIyQDF{NEG0
Jurkat NX[5PYRsTnWwY4Tpc44hSXO|YYm= M{eyOVEhcA>? NVnUXGNnTE2VTx?= NXTwUVNlUW6qaXLpeIlwdiCxZjDMR2sh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIEKuO|QyKM7:TR?= MXSyNVgyOjRzNB?=
KARPAS299 M4H3fGtqdmG|ZTDBd5NigQ>? NVjLdYl7OSCq NUPsdVBkTE2VTx?= NUHPNFhKUW6qaXLpeIlwdiCxZjDBUGsh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFIh|ryP NEW2TVYzOThzMkSxOC=>
PAE NXLLZZN{TnWwY4Tpc44hSXO|YYm= MVyxJIg> NFPBV45FVVOR NFTwZ3lKdmirYnn0bY9vKG:oIGTST2Ih[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuN|k6KM7:TR?= M1;WNVIyQDF{NEG0
BAF3 M4jJPWZ2dmO2aX;uJGF{e2G7 NGXKXIwzNTNiZB?= MYPEUXNQ MUjJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCrboP1cIlvKHKnY3XweI9zKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNU43PDNizszN NFO4dIkzOzd2MkK1Ni=>
KARPAS299 Ml7VR5l1d3SxeHnjJGF{e2G7 NW[2eIFSOi1|IHS= M1\RbGROW09? NGjodWhKSzVyPUCuNFY1OiEQvF2= MVuyN|c1OjJ3Mh?=
EBC1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVy3NkBp M1jhNGROW09? NXf3e3hSUUN3ME2wMlAzOyEQvF2= M{fNOlI{QTl|M{K4
HCT116 NE\lNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTVb2pFPzJiaB?= NH7TVVBFVVOR MojnTWM2OD1zND64NkDPxE1? M1j4flI{QTl|M{K4
MCF7 MlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnwVXJZPzJiaB?= NXPEPG1pTE2VTx?= NUTXcGJPUUN3ME25MlU5KM7:TR?= NVv0ZoNlOjN7OUOzNlg>
MDA-MB-231 NGXNNXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL0O|IhcA>? NHi4W4lFVVOR MkHrTWM2OD1zMD64JO69VQ>? MUeyN|k6OzN{OB?=
MKN45 NXvvfWlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoS4O|IhcA>? NFPRcohFVVOR M1fscGlEPTB;MD6wNVMh|ryP M{e5blI{QTl|M{K4
NCI-H441 NGTrRXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnJ[4M4PzJiaB?= NXXBeoliTE2VTx?= NXrqO5BiUUN3ME2xO{4zPSEQvF2= MY[yN|k6OzN{OB?=
NCI-H661 M1n5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTCT4ptPzJiaB?= MY\EUXNQ NIfOUIpKSzVyPUGxMlQ4KM7:TR?= NGj5T3UzOzl7M{OyPC=>
SK-MEL-28 NHPFcY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXG3NkBp NGfuXZFFVVOR M{nFOGlEPTB;MUCuPVch|ryP MXSyN|k6OzN{OB?=
SKOV3 NEmxUIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTpO|IhcA>? MlTwSG1UVw>? NWXmZldTUUN3ME2xNk45PSEQvF2= NG\0UIwzOzl7M{OyPC=>
SNU5 Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3XO|IhcA>? M3rBWGROW09? Ml3OTWM2OD1yLkCxOkDPxE1? NFniVGMzOzl7M{OyPC=>
NCI-H2228 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXS3NkBp NVPabGRNTE2VTx?= NYTqNYNLUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMUG4JO69VQ>? MYKyOFQ{OjlyOR?=
NCI-H3122 Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVi3NkBp NUTvVpJjTE2VTx?= MmXiTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvOTB6IN88US=> NYHXeYpFOjR2M{K5NFk>
NCI-H3122 NF:0T5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXu3NkBp MXfEUXNQ Mk\RTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25iaX6gbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGijcnLvdolv\yCDTFugS|EzPjmDIH31eIFvfCC5aYToJGlEPTBib3[gNE43OjNizszN M{PtUFI1PDN{OUC5
NCI-H3122 NF;nO|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjEeYVGPzJiaB?= M{PWcGROW09? M1XzcGlvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIHnuJIh2dWGwIF7DTU1JOzF{MjDj[YxteyCqYYLic5JqdmdiQVzLJGwyOTl4TTDteZRidnRid3n0bEBKSzVyIH;mJFAvQDN6IN88US=> NX7jRVgzOjR2M{K5NFk>
NIH-3T3 NGTuRWdMcW6jc3WgRZN{[Xl? NHLhWWIyKGh? M4G2cmROW09? M13Xd2lvcGmkaYTpc44hd2ZiaIXtZY4hf2muZDD0fZBmKEWPTESt[pV{\WRiQVzLJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCyaH;zdIhwenmuYYTl[EBCVEtibHX2[Ywhf2m2aDDJR|UxKG:oIECuNFgh|ryP NIXmUFAzPDR|MkmwPS=>
NIH-3T3 NF\Kc5VMcW6jc3WgRZN{[Xl? M{HYXlEhcA>? M{DqR2ROW09? NU\0SFNTUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BIOTJ4OVGgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD62NFUh|ryP M3zvZ|I1PDN{OUC5
NIH-3T3 M3vI[2tqdmG|ZTDBd5NigQ>? MlLCNUBp NVzhUnBxTE2VTx?= MXjJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIGOxNlA3YSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjZ{NjFOwG0> M1zxbFI1PDN{OUC5
NIH-3T3 MkfDT4lv[XOnIFHzd4F6 MVGxJIg> M4LjSmROW09? M3qyeWlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugUFEyQT[PIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwOESzJO69VQ>? NWC0Zpp3OjR2M{K5NFk>
NIH-3T3 MWfLbY5ie2ViQYPzZZk> MkfVNUBp MkjKSG1UVw>? Ml7aTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE2OlJibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOS5yMk[g{txO MoTjNlQ1OzJ7MEm=
BAF3 NWDXZlFVTnWwY4Tpc44hSXO|YYm= M2TGNlczKGh? Mo\ZSG1UVw>? MlTJTY5pcWKrdHnvckBw\iCQUF2vRWxMKHS{YX7z[oVkfGWmIHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODVzIN88US=> MXKyOFQ3QDZ|Mh?=
BAF3 M2rnV2N6fG:2b4jpZ{BCe3OjeR?= NGDHbIo4OiCq MnPXSG1UVw>? NUDTTHhTUUN3ME2wMlk5KM7:TR?= M1r1[FI1PDZ6NkOy
NIH-3T3 NVLlXVA1U2mwYYPlJGF{e2G7 MVyxJIg> M3e5N2lvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugSlEyPzSOIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwMU[1JO69VQ>? NYXGS2FQOjR6MUmxNVY>
NIH-3T3 M1LFeWtqdmG|ZTDBd5NigQ>? NGPv[2UyKGh? MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFOxNVU3YSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjR5ODFOwG0> NUi1N4NlOjR6MUmxNVY>
NIH-3T3 NVrmXZJbU2mwYYPlJGF{e2G7 NF74fnIyKGh? NGXr[WlKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGcyOjB{UjDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iBzLkG0PEDPxE1? MnvFNlQ5OTlzMU[=
NIH-3T3 NF\He3BMcW6jc3WgRZN{[Xl? NIjaeVkyKGh? NIHs[ZNKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJFEyPTGWaX7zJI12fGGwdDDlfJBz\XO|ZXSgZZN{\XO|ZXSgZZMheGixc4Doc{1CVEtibHX2[Ywhf2m2aDDJR|UxKG:oIEOuNFM6KM7:TR?= Mn;UNlQ5OTlzMU[=
KARPAS299 NWezZ2ljU2mwYYPlJGF{e2G7 MW[5NEBucW5? NX3WZYY6TE2VTx?= NG\NToJKdmirYnn0bY9vKG:oIF7QUU1nfXOnZDDBUGsheGixc4Doc5J6dGG2aX;uJIV5eHKnc4Pl[EB4cXSqIFnDOVAhd2ZiMD6xNUDPxE1? M{nDZVI1QTByN{Ww
MKN 45 NGPQVnBMcW6jc3WgRZN{[Xl? Mo[yNUBp MYTEUXNQ NWrYTZI6UW6qaXLpeIlwdiCxZjDjMW1mfCCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFIh|ryP NVOyVldDOjR7MEC3OVA>
A549 NVH2bHFxS3m2b4TvfIlkKEG|c3H5 NY[1eFlxPDhiaB?= MmrMSG1UVw>? MkTWTWM2OCCxZjC0MlA5PCEQvF2= NHP1VZAzPDlyMEizNC=>
NCI-H1975 NEP2WoJEgXSxdH;4bYMhSXO|YYm= MmLhOFghcA>? NIX4eVNFVVOR MmDVTWM2OCCxZjC3MlU2OSEQvF2= NHTuWYMzPDlyMEizNC=>
NCI-H1993 NU\JdVBSS3m2b4TvfIlkKEG|c3H5 NWTEcIxzPDhiaB?= NF3pN2FFVVOR NX73OXFHUUN3MDDv[kAxNjB4MTFOwG0> NYfBRlJtOjR7MEC4N|A>
NCI-H1993 NX\wUGhuSXCxdH;zbZMhSXO|YYm= M2CyN|Eh|ryP MnLsNlQhcA>? MnT6SG1UVw>? MXTkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m| M{W0blI1QTByOEOw
NIH-3T3 M3TKdGN6fG:2b4jpZ{BCe3OjeR?= MkjjOFghcA>? MXjEUXNQ MmXCTWM2OCCxZjCwMlM3PCEQvF2= NWjlTHB1OjR7MEC4N|A>
EBC1 MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLyO|IhcA>? MnexSG1UVw>? NHznTohKSzVyIH;mJFAvODB4OTFOwG0> M{KzcVI1QTByOEOx
KARPAS299 Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHVb|BnPzJiaB?= NIHZZWFFVVOR NXvEeWg2UUN3MDDv[kAxNjJizszN MYWyOFkxODh|MR?=
NB1 NVzoWHFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTlzLkm4JI5O NXTwSIJSW0GQR1XS
NCI-SNU-5 M4LlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HEOGlEPTB;MUC1Mlc2KG6P MlrZV2FPT0WU
SR NWHTeYozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfvSY9KSzVyPUGyOk4{OSCwTR?= NEfiS5FUSU6JRWK=
SF539 Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnsTWM2OD1{MESuNlQhdk1? NW\Ec3Z1W0GQR1XS
SU-DHL-1 Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoeyTWM2OD1|M{[uPFIhdk1? MYnTRW5ITVJ?
SCC-3 MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXmZlJyUUN3ME2zOVYvPzZibl2= NUWzbVh[W0GQR1XS
DEL NH3RNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LzSGlEPTB;M{[5Mlkhdk1? M3;RenNCVkeHUh?=
CTV-1 NWjnc5k{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrhVXhKSzVyPUW5Ok41QCCwTR?= M2L3THNCVkeHUh?=
EM-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\ZTWM2OD14MEGuN|Qhdk1? NXXU[FE2W0GQR1XS
MHH-CALL-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1i0d2lEPTB;NkiyMlU4KG6P NIjKSmNUSU6JRWK=
KM12 MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTdyNj65JI5O NHHLeIhUSU6JRWK=
KINGS-1 NV;pNWZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfLR|ZKSzVyPUe0PU44PSCwTR?= M1P3eHNCVkeHUh?=
MEG-01 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfFN3JKSzVyPUi1O{43PiCwTR?= MkXPV2FPT0WU
BV-173 Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFwMEW5PVch|ryP NEfNWI5USU6JRWK=
LAMA-84 NVnFeGVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzjPIE3UUN3ME2xMlM5Ojh{IN88US=> M13mbHNCVkeHUh?=
KARPAS-299 NEHoW2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXqTWM2OD1zLkSwPFYyKM7:TR?= Mn22V2FPT0WU
K-562 NXj0eGpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTFwN{KyOlkh|ryP NW\yO2Y6W0GQR1XS
SK-LMS-1 NEfUbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfEXoEyUUN3ME2xMlc3QDZ5IN88US=> NV3ESlRIW0GQR1XS
MOLT-16 M{LGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnGyTWM2OD1zLkm1OVc2KM7:TR?= NYHiVZh3W0GQR1XS
CMK M4naTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITJN3pKSzVyPUGuPVYyPTlizszN M1PqcnNCVkeHUh?=
ST486 MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LxS2lEPTB;Mj60N|A4OyEQvF2= Mnn1V2FPT0WU
CI-1 NIOzeZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTJwNEm2OVkh|ryP M2DKdnNCVkeHUh?=
KP-N-RT-BM-1 NIPaWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITqOXNKSzVyPUKuO|AyOjJizszN NHL5ZmFUSU6JRWK=
ALL-PO NFy3O|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TLZ2lEPTB;Mz6xPFIxPyEQvF2= MXfTRW5ITVJ?
KS-1 NGL6NY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[zdFNKSzVyPUOuNlEzOjVizszN MlPhV2FPT0WU
Becker NWjPXJR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLtTWM2OD12LkKzPVMh|ryP MkHaV2FPT0WU
GDM-1 NFT6Sm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rQb2lEPTB;ND6yOFYyPyEQvF2= NGHaOWtUSU6JRWK=
BC-1 NUHjT3VKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PFcGlEPTB;ND60PVI4PyEQvF2= M{j3fXNCVkeHUh?=
NB14 MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLDT41DUUN3ME20Mlg{PTJ2IN88US=> NW\ZVmQ2W0GQR1XS
NOS-1 NX7PXW8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Tr[2lEPTB;NT6zN|g4PCEQvF2= NFTFO3lUSU6JRWK=
MZ1-PC M1O4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rvdmlEPTB;NT64NlE2OSEQvF2= NV;rRpJiW0GQR1XS
A498 MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS0TWM2OD14LkC4OFc{KM7:TR?= M{PtU3NCVkeHUh?=
EW-16 Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDQW|Y3UUN3ME22MlM4Pzd|IN88US=> M17IfXNCVkeHUh?=
NALM-6 MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDaZZFzUUN3ME22MlY5Ozh5IN88US=> NIrXWYpUSU6JRWK=
EB-3 NFS2PHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rCTWlEPTB;Nz6wO|I{OyEQvF2= MmTHV2FPT0WU
697 NXLTUmp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVu5[m9FUUN3ME25MlI1OzJ7IN88US=> Ml7lV2FPT0WU
Ramos-2G6-4C10 NFWxXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PhV2lEPTB;OT61PVg1OiEQvF2= M2OwfHNCVkeHUh?=
KNS-81-FD NHO3NFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXnPItkUUN3ME25MlY6PjV|IN88US=> MlPQV2FPT0WU
HUTU-80 NWfCVW1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEe4bIVKSzVyPUmuO|Q3PDJizszN MlvMV2FPT0WU
LS-411N NGq0RmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXKTWM2OD1zMD6wOVY4KM7:TR?= NUnYZnlXW0GQR1XS
RPMI-8402 NG\ETpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDGXIJ2UUN3ME2xNE4yOTZizszN M1LVOHNCVkeHUh?=
KU812 M3rucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVm3TmFWUUN3ME2xNE4zQTlzIN88US=> M{XBXHNCVkeHUh?=
EW-1 M{jidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFyLkS0NlUh|ryP MYjTRW5ITVJ?
HC-1 MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHtTWM2OD1zMD60PFQ1KM7:TR?= NVTVOGU6W0GQR1XS
NB69 M1noSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLKTWM2OD1zMD61NFQ{KM7:TR?= NVHzRVZRW0GQR1XS
MFH-ino MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLTT3hKSzVyPUGwMlg{ODNizszN MWHTRW5ITVJ?
CCRF-CEM M3Pme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m3bWlEPTB;MUGuOVk4KM7:TR?= MXfTRW5ITVJ?
SK-N-DZ MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXQN4VKSzVyPUGyMlA1OzZizszN MoPVV2FPT0WU
NCI-H720 MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LOb2lEPTB;MUKuNVcxPSEQvF2= MlLKV2FPT0WU
HCC1187 M1vqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTF{LkKwOFEh|ryP M37HbXNCVkeHUh?=
IST-SL2 NFvPRWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP3TWM2OD1zMj60PFczKM7:TR?= NWnRTmtwW0GQR1XS
KE-37 M3XW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTF{Lke5OlYh|ryP M32xe3NCVkeHUh?=
HCC1599 MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv1TWM2OD1zMj65NFY6KM7:TR?= NInrWFNUSU6JRWK=
A4-Fuk MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TxdGlEPTB;MUKuPVU5PiEQvF2= NFTmNVZUSU6JRWK=
NKM-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF|LkK5NlUh|ryP NWPVR2s4W0GQR1XS
BE-13 MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLoTWM2OD1zMz63PVg6KM7:TR?= Ml25V2FPT0WU
MV-4-11 M4fJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfyTWM2OD1zND6wN|I1KM7:TR?= MUPTRW5ITVJ?
OPM-2 Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTGTWM2OD1zND60NFg2KM7:TR?= MWDTRW5ITVJ?
KARPAS-422 MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHHbIdKSzVyPUG0MlUyOjZizszN MXjTRW5ITVJ?
RPMI-8226 M1zBTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XwNWlEPTB;MUSuPFkyPSEQvF2= NIGwOIJUSU6JRWK=
KARPAS-45 M1L4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLiTFlqUUN3ME2xOU44PzF4IN88US=> M3y5WnNCVkeHUh?=
SK-PN-DW NGfq[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDHcW5lUUN3ME2xOU45PjNzIN88US=> MmCyV2FPT0WU
LC-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLsTWM2OD1zNj6xOVA3KM7:TR?= NUPIUWhPW0GQR1XS
NCI-H1648 M2WxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnPTWM2OD1zNj6yOVQh|ryP M3S0cXNCVkeHUh?=
RL95-2 NUnsNY5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITmeXdKSzVyPUG2MlM6PzhizszN M1jid3NCVkeHUh?=
KNS-42 NYHaZ5Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LteWlEPTB;MU[uO|I4PCEQvF2= Mn7TV2FPT0WU
RPMI-6666 NVjWe|dWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTF4LkmyNVEh|ryP NIDaRXVUSU6JRWK=
SIG-M5 MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjwN|R3UUN3ME2xO{4yQTB|IN88US=> NHu3dWxUSU6JRWK=
VA-ES-BJ MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF5Lke0OVEh|ryP MVzTRW5ITVJ?
MONO-MAC-6 MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTF5LkmzNVIh|ryP MV7TRW5ITVJ?
LAN-6 M3vHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTF6Lke1OVch|ryP MVHTRW5ITVJ?
A388 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfwcGJKUUN3ME2xPU4{ODV7IN88US=> M2iyZ3NCVkeHUh?=
SK-NEP-1 M2e1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\STWM2OD1{MD6yNVMzKM7:TR?= M4PGd3NCVkeHUh?=
TE-10 NF;sXlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPkWlJKSzVyPUKwMlUzOjFizszN NX3mZXRNW0GQR1XS
HL-60 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJyLkmwPVkh|ryP NHq4cWxUSU6JRWK=
MC116 MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJzLkeyNlEh|ryP MoH4V2FPT0WU
SW962 MoPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrWTWM2OD1{MT63PVE2KM7:TR?= MVfTRW5ITVJ?
NOMO-1 Mlr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjtTZBKSzVyPUKyMlY2PjRizszN NYrTc2UyW0GQR1XS
CTB-1 NHXhUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlezTWM2OD1{Mj64OlcyKM7:TR?= MoTGV2FPT0WU
MRK-nu-1 MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vKPWlEPTB;MkKuPVA4PCEQvF2= NGPBTY1USU6JRWK=
GR-ST Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL5TWM2OD1{Mz63OkDPxE1? NUHQfJp{W0GQR1XS
HH MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJ2LkCwN{DPxE1? NXjHXo4zW0GQR1XS
NCI-H1963 NGHMU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWX4[FRYUUN3ME2yOE4xPzh{IN88US=> NV7qe29NW0GQR1XS
QIMR-WIL M1:0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTJ2Lki3O|Ih|ryP NXrZWGo2W0GQR1XS
CGTH-W-1 NH:1S2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJ3LkC3NlMh|ryP MVPTRW5ITVJ?
LP-1 NEPLcYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\GRW51UUN3ME2yOU43PTVzIN88US=> NIXkV5dUSU6JRWK=
NCI-H748 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJ4LkWxN|ch|ryP NYDJe4xHW0GQR1XS
PF-382 NYfRU3FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;2TWM2OD1{Nz6yNlI{KM7:TR?= M2XJ[nNCVkeHUh?=
ATN-1 NF;YelFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELHNW9KSzVyPUK3MlM4OzJizszN Mo\RV2FPT0WU
L-540 MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojpTWM2OD1{Nz62OFU6KM7:TR?= MmTZV2FPT0WU
LXF-289 NFP1W3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJ5Lke1NVkh|ryP NG\kV4RUSU6JRWK=
LS-513 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUn0dXdtUUN3ME2yPE4yQDB5IN88US=> NIjibo1USU6JRWK=
NCI-H1581 NWHPPIxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj2TWM2OD1|MD6zPVc3KM7:TR?= M{jzbHNCVkeHUh?=
ES6 NUPqV3dqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\acXBuUUN3ME2zNE43QDl7IN88US=> MU\TRW5ITVJ?
SW982 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTNyLki1OlYh|ryP MoTnV2FPT0WU
DOHH-2 M1XjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvJO4I{UUN3ME2zNU42QDl|IN88US=> MkfVV2FPT0WU
DB NHLpT|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTN|Lkm0N|Eh|ryP NWfmPIpZW0GQR1XS
MPP-89 MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXPTWM2OD1|ND6xO|U3KM7:TR?= NUD1TJQ{W0GQR1XS
LB831-BLC MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTN2LkWxPFQh|ryP NE[0b5VUSU6JRWK=
NB5 MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrtZ2pKSzVyPUO0Mlg2OzVizszN M{DXTnNCVkeHUh?=
GB-1 NUDMU3ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn60TWM2OD1|NT6wOFY6KM7:TR?= M1rYSnNCVkeHUh?=
TE-15 NV7iNGZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq5[2xKSzVyPUO1MlIzOzhizszN NGfNZVFUSU6JRWK=
LC4-1 NHPhRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH4bpMzUUN3ME2zOU4{QDR5IN88US=> M{fpbHNCVkeHUh?=
NCI-H747 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTN4LkGzOlkh|ryP M3;aSXNCVkeHUh?=
NTERA-S-cl-D1 M1TnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTN6LkezOFch|ryP M3\IdXNCVkeHUh?=
SK-MM-2 NIHue4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3MbVVKSzVyPUSwMlEyPDZizszN MonwV2FPT0WU
TGW M4jUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj1UnpKSzVyPUSxMlA2PjNizszN MnHJV2FPT0WU
ONS-76 M1j6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rxOmlEPTB;NEKuOFg5OyEQvF2= NYC3XlBHW0GQR1XS
CPC-N NHWyXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLITWM2OD12Mj65PVcyKM7:TR?= Mor5V2FPT0WU
ES4 MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTR2LkSxOVMh|ryP MmH0V2FPT0WU
Daudi MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\vTWM2OD12NT6wPFI4KM7:TR?= NHzXcmJUSU6JRWK=
MOLT-4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTR3LkC4OVMh|ryP MVvTRW5ITVJ?
HT-144 M3XKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlj5TWM2OD12Nj63NlYh|ryP M3fqWnNCVkeHUh?=
SW872 NYXMfYE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPyZYZKSzVyPUS4MlE6OzNizszN NIi0PHdUSU6JRWK=
D-283MED NInhS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL2bo5KSzVyPUS4MlM2PDJizszN NITXNmVUSU6JRWK=
NCI-H2126 M3PYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP1UIhKSzVyPUS4Mlg1PzZizszN M1TZUXNCVkeHUh?=
NCI-SNU-16 NV;WZ296T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\yTWM2OD12OT6yNVQ{KM7:TR?= MkH6V2FPT0WU
CESS NGPKb3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTR7LkWwPFgh|ryP NVTNdVNzW0GQR1XS
A101D M1rybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvhclYzUUN3ME20PU46PzN4IN88US=> M3HV[HNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]

Protocol

Kinase Assay:

[1]

+ Expand

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research:

[1]

+ Expand
  • Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • Concentrations: 0-256 nM
  • Incubation Time: 1 hour
  • Method:

    Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231
  • Formulation: --
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+30% PEG 300+dd H2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.34
Formula

C21H22Cl2FN5O

CAS No. 877399-52-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03052608 Not yet recruiting Carcinoma, Non-Small-Cell Lung Pfizer March 2017 Phase 3
NCT02838420 Recruiting Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer Hoffmann-La Roche August 2016 Phase 3
NCT02836847 Recruiting Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer Shanghai Jiao Tong University School of Medicine|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Eastern Hepatobiliary Surgery Hospital|Huashan Hospital July 2016 Phase 2
NCT02946359 Recruiting Lung Adenocarcinoma Metastatic Chinese PLA General Hospital July 2016 Phase 2
NCT02679170 Recruiting Non-Small Cell Lung Cancer Pfizer June 2016 --
NCT02767804 Recruiting Non-small Cell Lung Cancer Xcovery Holding Company, LLC June 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • Answer:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

Related Antibodies

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products

Tags: buy Crizotinib (PF-02341066) | Crizotinib (PF-02341066) supplier | purchase Crizotinib (PF-02341066) | Crizotinib (PF-02341066) cost | Crizotinib (PF-02341066) manufacturer | order Crizotinib (PF-02341066) | Crizotinib (PF-02341066) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID